Cargando…
Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
Amikacin liposome inhalation suspension (ALIS) is a key drug for the treatment of refractory Mycobacterium avium complex pulmonary disease (MAC-PD). Although cases of drug-induced interstitial lung disease (DIILD) by ALIS have been reported, its diagnosis is challenging due to overlapping existing p...
Autores principales: | Hashimoto, Kazuki, Nii, Takuro, Sumitani, Hitoshi, Yokoyama, Masashi, Miyamoto, Satoshi, Mihashi, Yasuhiro, Nagata, Yuka, Matsuki, Takanori, Tsujino, Kazuyuki, Miki, Keisuke, Kida, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576464/ https://www.ncbi.nlm.nih.gov/pubmed/37840829 http://dx.doi.org/10.2147/IDR.S427544 |
Ejemplares similares
-
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019) -
Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019) -
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021) -
Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022) -
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)